
    
      Primary Endpoint To determine the effect of a topical application of Valchlor on human
      subjects at the clinically approved dose.

      Secondary Endpoint To establish the efficacy of cholecalciferol (vitamin D3) in reducing skin
      irritation 48 hours after topical application of Valchlor.
    
  